Jon Snodgres - 07 Oct 2022 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Reporting relationship: Chief Financial Officer
Issuer ticker: RGEN
Reported as of: 07 Oct 2022
Net transaction value: +$27,736
SEC form: 4
Accepted by SEC: 11 Oct 2022, 17:00:08 UTC
Prior SEC filing: 17 Aug 2022
Next SEC filing: 17 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Kimberly Brown (Attorney in Fact)

Key filing fact

Jon Snodgres filed Form 4 for REPLIGEN CORP (RGEN) on 11 Oct 2022.

Key facts

This page summarizes Jon Snodgres's Form 4 filing for REPLIGEN CORP (RGEN).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Oct 2022, 17:00.

Change

Previous filing in this sequence was filed on 17 Aug 2022.
Current net transaction value: +$27,736.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RGEN transaction

Common Stock

Options Exercise

Transaction value: $27,736
Shares: +466
Change %: +1.4%
Price: $59.52
Shares after: 34,972
Date: 07 Oct 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RGEN transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: +466
Change %: +28%
Price: $0.000000
Shares after: 2,108
Date: 07 Oct 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 466
Exercise price: $59.52
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Exercise of options was effected pursuant to a 10(b)5-1 trading plan adopted on September 6, 2022.

Footnote F2

This option is fully vested and exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .